April 27 (Reuters) - Oruka Therapeutics said on Monday that interim results showed its experimental drug helped clear psoriasis within 16 weeks, meeting the main goal of a mid-stage study and sending ...

Oruka Therapeutics’ long-acting plaque psoriasis candidate cleared the skin of 63.5% of patients in a phase 2a trial, leading ...

Measures of skin discoloration had a greater effect on quality of life in patients with psoriasis than overall clearance of skin lesions.

ORKA-001 also met secondary endpoints at 16 weeks, and updated data support the potential for once-yearly dosing ...

Gelfand, MD, of the University of Pennsylvania in Philadelphia, highlighted the growing recognition of psoriasis as a ...

A therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the ...

At week 16, 40 of 63 participants receiving ORKA-001 achieved PASI 100, corresponding to complete skin clearance.

Oruka Therapeutics shares gained after the company announced positive results for its Phase 2a trial of a psoriasis treatment. The stock jumped 22% to $84 in premarket trading Monday. Through Friday's ...

Fall and winter tend to be colder and drier than spring and summer — and that can have an effect on psoriasis symptoms, since cold, dry air is a known psoriasis trigger. There are also fewer hours of ...

Psoriasis is a skin condition that causes the formation of thick, scaly patches on the body. It’s commonly found on the elbows, knees or scalp but can occur nearly anywhere on the skin. Cold weather ...

Psoriasis isn’t just a skin condition — it’s an autoimmune disease that can affect your whole body and wellbeing. From medical treatments to lifestyle changes, there are more ways than ever to manage ...